80 related articles for article (PubMed ID: 21291797)
21. Lipoprotein-associated phospholipase A2 and risk of stroke.
Gorelick PB
Am J Cardiol; 2008 Jun; 101(12A):34F-40F. PubMed ID: 18549870
[TBL] [Abstract][Full Text] [Related]
22. Lp-PLA(2) as a marker of cardiovascular diseases.
Bhatti S; Hakeem A; Cilingiroglu M
Curr Atheroscler Rep; 2010 Mar; 12(2):140-4. PubMed ID: 20425250
[TBL] [Abstract][Full Text] [Related]
23. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM
J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676
[TBL] [Abstract][Full Text] [Related]
24. Darapladib.
Bui QT; Wilensky RL
Expert Opin Investig Drugs; 2010 Jan; 19(1):161-8. PubMed ID: 20001561
[TBL] [Abstract][Full Text] [Related]
25. Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway.
Song JX; Ren JY; Chen H
J Cardiovasc Pharmacol; 2011 Feb; 57(2):213-22. PubMed ID: 21052011
[TBL] [Abstract][Full Text] [Related]
26. Darapladib: an emerging therapy for atherosclerosis.
Corson MA
Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):241-8. PubMed ID: 20660537
[TBL] [Abstract][Full Text] [Related]
27. Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.
Carlquist JF; Muhlestein JB; Anderson JL
Expert Rev Mol Diagn; 2007 Sep; 7(5):511-7. PubMed ID: 17892360
[TBL] [Abstract][Full Text] [Related]
28. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease.
Tsimikas S; Tsironis LD; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2094-9. PubMed ID: 17626905
[TBL] [Abstract][Full Text] [Related]
29. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS
Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668
[TBL] [Abstract][Full Text] [Related]
30. Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target.
Macphee C; Benson GM; Shi Y; Zalewski A
Expert Opin Investig Drugs; 2005 Jun; 14(6):671-9. PubMed ID: 16004595
[TBL] [Abstract][Full Text] [Related]
31. Lp-PLA2 Inhibition-The Atherosclerosis Panacea?
Karakas M; Koenig W
Pharmaceuticals (Basel); 2010 Apr; 3(5):1360-1373. PubMed ID: 27713307
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.
Colley KJ; Wolfert RL; Cobble ME
EPMA J; 2011 Mar; 2(1):27-38. PubMed ID: 21654904
[TBL] [Abstract][Full Text] [Related]
33. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).
Magrioti V; Kokotos G
Expert Opin Ther Pat; 2013 Mar; 23(3):333-44. PubMed ID: 23294257
[TBL] [Abstract][Full Text] [Related]
34. What is the future for drug development in atherosclerosis and dyslipidaemia?
Suckling K
Expert Opin Drug Discov; 2009 Jan; 4(1):1-3. PubMed ID: 23480330
[TBL] [Abstract][Full Text] [Related]
35. The identification of occult cardiovascular disease through the use of a novel biomarker: a case report.
Bale B; Doneen A; Wegner M
J Clin Lipidol; 2009 Oct; 3(5):351-4. PubMed ID: 21291834
[No Abstract] [Full Text] [Related]
36. Plasma Lipoprotein-Associated Phospholipase A2 Affects Cognitive Impairment in Patients with Cerebral Microbleeds.
Liu L; Zhang X; Jiang N; Liu Y; Wang Q; Jiang G; Li X; Zhao L; Zhai Q
Neuropsychiatr Dis Treat; 2023; 19():635-646. PubMed ID: 36987525
[TBL] [Abstract][Full Text] [Related]
37. The correlation between lipoprotein associated phospholipase A
Chen YH; Li WC; Chen YC; Yeh WC; Yu W; Hung HY; Jie XX; Chen JY
Int J Immunopathol Pharmacol; 2021; 35():20587384211048562. PubMed ID: 34796753
[TBL] [Abstract][Full Text] [Related]
38. Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis.
Wang Y; Zhou B; Zhou P; Yao Y; Cui Q; Liu Y; Yang J; Wu S; Zhao X; Zhou Y
J Cell Mol Med; 2018 Apr; 22(4):2329-2336. PubMed ID: 29424477
[TBL] [Abstract][Full Text] [Related]
39. Blood pressure-lowering effect of Korean red ginseng associated with decreased circulating Lp-PLA2 activity and lysophosphatidylcholines and increased dihydrobiopterin level in prehypertensive subjects.
Cha TW; Kim M; Kim M; Chae JS; Lee JH
Hypertens Res; 2016 Jun; 39(6):449-56. PubMed ID: 26843120
[TBL] [Abstract][Full Text] [Related]
40. Low-density lipoprotein, its susceptibility to oxidation and the role of lipoprotein-associated phospholipase A2 and carboxyl ester lipase lipases in atherosclerotic plaque formation.
Burchardt P; Zurawski J; Zuchowski B; Kubacki T; Murawa D; Wiktorowicz K; Wysocki H
Arch Med Sci; 2013 Feb; 9(1):151-8. PubMed ID: 23515030
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
